Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SPY072
SPY002-072 · 2 trials · 9 indications
HiSCR75 is defined as at least a 75% reduction from baseline in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining tunnel count
The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.
The score combines 5 disease activity variables (back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain/swelling and measure of inflammation) to measure disease activity. Lowest score is 0.6 and increases as disease worsens. Higher scores indicate greater disease activity.
The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts (TJC and SJC), and at least 20% improvement in 3 out of 5 other disease activity measures (patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire, and measure of inflammation) will be assessed.
| Arm | Type | Description |
|---|---|---|
| SPY072 + bimekizumab | EXPERIMENTAL | Participants receive SPY072 + bimekizumab |
| Placebo + bimekizumab | PLACEBO_COMPARATOR | Participants receive matching placebo for SPY072 + bimekizumab |
| Rheumatoid Arthritis, Dose Regimen 1 | EXPERIMENTAL | Participants will receive double-blind dosing regimen 1 of SPY072 |
| Rheumatoid Arthritis, Dose Regimen 2 | EXPERIMENTAL | Participants will receive double-blind dosing regimen 2 of SPY072 |
| Psoriatic Arthritis | EXPERIMENTAL | Participants will receive double-blind dose of SPY072 |
| Axial Spondyloarthritis | EXPERIMENTAL | Participants will receive double-blind dose of SPY072 |
| Rhematoid Arthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Psoriatic Arthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Axial Spondyloarthritis Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo |
| Name | Type | Description |
|---|---|---|
| SPY072 | DRUG | Solution for SC injection |
| Placebo | DRUG | Matching placebo for SC injection |
| bimekizumab | DRUG | Advanced standard of care |
| SPY002-072 | DRUG | Experimental |
Inclusion Criteria: * Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening. * Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1. * Total abscess...
Top 20 of 30 competitors
SPY002-072 is an investigational small-molecule drug being developed by Spyre Therapeutics for rheumatoid arthritis and other rheumatic diseases. It is designed to target TL1A, a protein target in the immunology space. SPY002-072 is currently in Phase 2 clinical development and has not been approved for any use.
SPY002-072 is being studied as a treatment for rheumatoid arthritis, along with psoriatic arthritis, axial spondyloarthritis, and other rheumatic joint diseases. It is an investigational therapy in Phase 2 testing and is not yet available as an approved treatment for rheumatoid arthritis or any other condition.
SPY002-072 targets TL1A, a protein target involved in immunology. By binding TL1A, the small molecule is designed to act on this pathway in inflammatory rheumatic disease. TL1A is the only molecular target identified for SPY002-072 in its development program.
SPY002-072 is being developed by Spyre Therapeutics, Inc., which trades under the ticker SYRE. Spyre Therapeutics is the sponsor of the Phase 2 study evaluating SPY002-072 in rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
SPY002-072 is in Phase 2 clinical development. Its single registered trial is a Phase 2 study that is currently active but no longer recruiting participants. SPY002-072 is investigational and has not been approved by the FDA for rheumatoid arthritis or any other indication.
SPY002-072 is being evaluated in one clinical trial, NCT07148414, titled A Study of SPY072 in Rheumatic Disease. The Phase 2 trial is active but not recruiting, is randomized, double-blind, and placebo-controlled, and has an enrollment of 285 participants across the United States, Bulgaria, Czechia, Georgia, Moldova, Poland, Spain, and Ukraine.